Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma
The prognosis of patients with advanced cutaneous melanoma has radically changed in the past decade. Nevertheless, primary or acquired resistance to systemic treatment occurs in many cases, highlighting the need for novel treatment strategies. This review has the purpose of summarizing the current a...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/2/271 |
| _version_ | 1797495369903374336 |
|---|---|
| author | Francesca Comito Rachele Pagani Giada Grilli Francesca Sperandi Andrea Ardizzoni Barbara Melotti |
| author_facet | Francesca Comito Rachele Pagani Giada Grilli Francesca Sperandi Andrea Ardizzoni Barbara Melotti |
| author_sort | Francesca Comito |
| collection | DOAJ |
| description | The prognosis of patients with advanced cutaneous melanoma has radically changed in the past decade. Nevertheless, primary or acquired resistance to systemic treatment occurs in many cases, highlighting the need for novel treatment strategies. This review has the purpose of summarizing the current area of interest for the treatment of metastatic or unresectable advanced cutaneous melanoma, including data from recently completed or ongoing clinical trials. The main fields of investigation include the identification of new immune checkpoint inhibitors (anti-LAG3, GITR agonist and anti-TIGIT), adoptive cell therapy, vaccines, engineered TCR therapy, IL-2 agonists, novel targets for targeted therapy (new MEK or RAF inhibitors, HDAC, IDO, ERK, Axl, ATR and PARP inhibitors), or combination strategies (antiangiogenetic agents plus immune checkpoint inhibitors, intra-tumoral immunotherapy in combination with systemic therapy). In many cases, only preliminary efficacy data from early phase trials are available, which require confirmation in larger patient cohorts. A more in-depth knowledge of the biological effects of the molecules and identifying predictive biomarkers remain crucial for selecting patient populations most likely to benefit from novel emerging treatment strategies. |
| first_indexed | 2024-03-10T01:47:09Z |
| format | Article |
| id | doaj.art-6876484b754d48e7a32d3e1ba7461a74 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:47:09Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-6876484b754d48e7a32d3e1ba7461a742023-11-23T13:12:12ZengMDPI AGCancers2072-66942022-01-0114227110.3390/cancers14020271Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous MelanomaFrancesca Comito0Rachele Pagani1Giada Grilli2Francesca Sperandi3Andrea Ardizzoni4Barbara Melotti5Medical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15-40138 Bologna, ItalyMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15-40138 Bologna, ItalyMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15-40138 Bologna, ItalyMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15-40138 Bologna, ItalyMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15-40138 Bologna, ItalyMedical Oncology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni, 15-40138 Bologna, ItalyThe prognosis of patients with advanced cutaneous melanoma has radically changed in the past decade. Nevertheless, primary or acquired resistance to systemic treatment occurs in many cases, highlighting the need for novel treatment strategies. This review has the purpose of summarizing the current area of interest for the treatment of metastatic or unresectable advanced cutaneous melanoma, including data from recently completed or ongoing clinical trials. The main fields of investigation include the identification of new immune checkpoint inhibitors (anti-LAG3, GITR agonist and anti-TIGIT), adoptive cell therapy, vaccines, engineered TCR therapy, IL-2 agonists, novel targets for targeted therapy (new MEK or RAF inhibitors, HDAC, IDO, ERK, Axl, ATR and PARP inhibitors), or combination strategies (antiangiogenetic agents plus immune checkpoint inhibitors, intra-tumoral immunotherapy in combination with systemic therapy). In many cases, only preliminary efficacy data from early phase trials are available, which require confirmation in larger patient cohorts. A more in-depth knowledge of the biological effects of the molecules and identifying predictive biomarkers remain crucial for selecting patient populations most likely to benefit from novel emerging treatment strategies.https://www.mdpi.com/2072-6694/14/2/271cutaneous melanomametastatic melanomanovel targetsvaccineimmunotherapytargeted therapy |
| spellingShingle | Francesca Comito Rachele Pagani Giada Grilli Francesca Sperandi Andrea Ardizzoni Barbara Melotti Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma Cancers cutaneous melanoma metastatic melanoma novel targets vaccine immunotherapy targeted therapy |
| title | Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma |
| title_full | Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma |
| title_fullStr | Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma |
| title_full_unstemmed | Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma |
| title_short | Emerging Novel Therapeutic Approaches for Treatment of Advanced Cutaneous Melanoma |
| title_sort | emerging novel therapeutic approaches for treatment of advanced cutaneous melanoma |
| topic | cutaneous melanoma metastatic melanoma novel targets vaccine immunotherapy targeted therapy |
| url | https://www.mdpi.com/2072-6694/14/2/271 |
| work_keys_str_mv | AT francescacomito emergingnoveltherapeuticapproachesfortreatmentofadvancedcutaneousmelanoma AT rachelepagani emergingnoveltherapeuticapproachesfortreatmentofadvancedcutaneousmelanoma AT giadagrilli emergingnoveltherapeuticapproachesfortreatmentofadvancedcutaneousmelanoma AT francescasperandi emergingnoveltherapeuticapproachesfortreatmentofadvancedcutaneousmelanoma AT andreaardizzoni emergingnoveltherapeuticapproachesfortreatmentofadvancedcutaneousmelanoma AT barbaramelotti emergingnoveltherapeuticapproachesfortreatmentofadvancedcutaneousmelanoma |